CSIMarket
 
Nighthawk Biosciences inc   (NHWK)
Other Ticker:  
 
 
Price: $0.4135 $0.03 8.959%
Day's High: $0.43 Week Perf: 16.15 %
Day's Low: $ 0.37 30 Day Perf: -6.02 %
Volume (M): 173 52 Wk High: $ 0.94
Volume (M$): $ 72 52 Wk Avg: $0.57
Open: $0.37 52 Wk Low: $0.26



 Market Capitalization (Millions $) 11
 Shares Outstanding (Millions) 26
 Employees -
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -53
 Cash Flow (TTM) (Millions $) -8
 Capital Exp. (TTM) (Millions $) 3

Nighthawk Biosciences Inc
We are a fully integrated biopharmaceutical company that specializes in developing and commercializing therapies to enhance the immune system's response against a wide range of diseases, including cancer and infectious diseases. Our focus is on end-to-end development and commercialization, from discovery to clinical trials and commercial pipeline. We have recently launched Scorpion Biological Services, Inc. (Scorpion), our subsidiary that enables us to enhance efficiency and decrease dependence on third-party contract research and development biomanufacturing organizations. Additionally, we are in the process of acquiring Elusys Therapeutics, Inc., which supports our development of critical therapeutic innovations for the biodefense sector.

Our main platforms are the gp96 platform and RapidVax platform, which leverage gp96 to transport predefined antigens to stimulate an immune response. We have lead assets, such as HS-110 and HS-130, in various stages of clinical trials for non-small cell lung cancer and solid tumors. The RapidVax platform allows for the accelerated customization of vaccines to respond to biological threats.

In addition, we have a platform focused on targeting the Death Receptor 3/TNF receptor superfamily member 25 (DR3/TNFRSF25) cellular receptor to restore balance to the immune system. Our lead asset, PTX-35, is being evaluated in a Phase 1 clinical trial for advanced solid tumors.

Recently, we have entered into an agreement to acquire Elusys Therapeutics, Inc., a company focused on the commercialization of ANTHIM, a monoclonal antibody antitoxin for anthrax. ANTHIM has received marketing approvals in the U.S., Canada, Europe, and the UK. This acquisition will further strengthen our biodefense capabilities.

Overall, our goal is to decrease the time and increase the efficiency of drug development to accelerate the delivery and commercialization of novel immune activating therapies.


   Company Address: 627 Davis Drive, Suite 300 Morrisville 27560 NC
   Company Phone Number: 240-7133   Stock Exchange / Ticker: NYSEAMER NHWK
   NHWK is expected to report next financial results on March 30, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Partnership

Scorpius Holdings Stakes its Claim in the Biotech Elite: Accepted into BioMaP Consortium, Gaining Access to Funding and Federal Projects

Published Thu, Mar 14 2024 12:30 PM UTC

Scorpius Holdings Accepted as a Member of the US Government's BioMaP Consortium: Providing Access to Growth Funding and Enhanced Access to Federal ProjectsIn an exciting development for Scorpius Holdings, the renowned company has announced its acceptance as a member of the prestigious BioMaP Consortium, initiated by the US Government. This achievement will provide Scorpius H...

Shares

Sparking Success: Scorpius Holdings' Public Offering Ignites Growth in the CDMO Industry

Published Tue, Mar 12 2024 9:01 PM UTC

Scorpius Holdings Successfully Closes Public Offering, Fostering Growth in the Contract Development and Manufacturing Sector
Durham, NC - Scorpius Holdings, Inc. (NYSE American: SCPX) proudly announced the successful completion of its recent public offering, signaling a significant milestone for the integrated Contract Development and Manufacturing Organization (CDMO) an...

Stock Market Announcement

Scorpius Holdings, Inc. Charts Path for Growth with Proposed Public Offering of Common Stock

Published Thu, Mar 7 2024 9:18 PM UTC

Scorpius Holdings, Inc. Announces Proposed Public Offering of Common Stock: A Strategic Move for Growth
Scorpius Holdings, Inc. recently announced its plans for a public offering of common stock, signaling a strategic move for the integrated contract development and manufacturing organization (CDMO). With all shares to be sold by the Company, this offering is expected to...

Management Announcement

Scorpius Holdings Surpasses Expectations with Over 375% Sequential Revenue Growth in Q4 2023, Nighthawk Biosciences Inc Battles Net Loss and Negative Return on Equity

Published Thu, Mar 7 2024 1:30 PM UTC


In a surprising turn of events, Scorpius Holdings has announced estimates of a significant increase in revenue for the fourth quarter of 2023, surpassing expectations with a sequential growth of over 375% compared to the third quarter. Additionally, the company also forecasts a reduction in operating loss for the same period by approximately $3.3 million or 30%.
The...

Management Announcement

Scorpius Holdings Emerges: Revolutionizing Biomanufacturing and Ushering in a New Era for NightHawk Biosciences

Published Tue, Feb 6 2024 1:00 PM UTC



NightHawk Biosciences, now known as Scorpius Holdings, has successfully completed its transition into a pure-play, large molecule biomanufacturing contract development and manufacturing organization (CDMO). The company announced the name change and ticker symbol conversion to SCPX, effective from February 6, 2024. This article will outline the facts surrounding the...






 

Nighthawk Biosciences Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com